[S1 guidelines on malignant hyperthermia : Update 2018].
The prevalence of malignant hyperthermia (MH) in Germany is 1:2000-1:3000 and therefore more common than previously assumed, so that anesthesia personnel will more often be confronted with susceptible patients in the clinical setting. After the initial treatment with 2.5 mg/kg body weight dantrolene, further therapy using up to 10 mg/body weight dantrolene can be indicated for 24 h. Under these circumstances it is important to have a sufficient amount of water available for injection purposes. For outpatient anesthesia a stockage of dantrolene is not necessary as long as the use of MH trigger substances in general is strictly avoided. The introduction of Ryanodex® (Eagle Pharmaceuticals, Woodcliff Lake, NJ, USA), a preparation of dantrolene with clearly improved pharmacological properties, in the clinical practice has not yet been realized in Germany.